Amgen

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Retrieved on: 
Tuesday, April 2, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, AbbVie, Prader–Willi syndrome, Scripps Research, IGM, Horizon, Delusion, Executive, Harvey Mudd College, Patient, Acquisition, Rett syndrome, Doctor of Philosophy, Myenteric plexus, Chemistry, Research and development, Hallucination, Rare disease, Amgen, ACAD, FDA, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.
  • Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
  • “Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies,” said Steve Davis, Chief Executive Officer.
  • She joined Horizon in 2018 and served in roles of increasing responsibility that culminated at Executive Vice President, Research and Development.

KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

Retrieved on: 
Monday, April 1, 2024
Other Manufacturing, Research, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, CDMO, Novartis, Regulatory affairs, CGMP, Bayer, KBI, Chemical engineering, Multimedia, Amgen, Rensselaer Polytechnic Institute, Engineering

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.

Key Points: 
  • KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.
  • Peter will lead KBI’s Quality and Regulatory Affairs team, spearheading compliance and regulatory initiatives for customers worldwide and positioning KBI to provide the services, expertise, and leadership to partner with health authorities on regulatory policy.
  • "We have made a commitment to establishing KBI Biopharma as a thought leader and catalyst for change in Regulatory Affairs within the biopharma sector,” said J.D.
  • "Peter's addition to our team bolsters our expertise in quality and regulatory compliance and facilitates our continued transformation in support of our current and future customers.

Ephicacy Bolsters Leadership Team with Four New Hires

Retrieved on: 
Wednesday, March 27, 2024
Technology, Consulting, Health Technology, Professional Services, Biotechnology, Data Analytics, Pharmaceutical, Health, Data Management, Outsourcing Business, Financial management, ChromeOS, Growth, CFO, Cytel, Biostatistics, Head, Contract research organization, Genpact, FP&A, Accenture, IQVIA, FP, Amgen, Data management

Ephicacy Consulting Group, Inc., (“Ephicacy”), a leading biometrics Contract Research Organization (“CRO”) and global provider of statistical programming, biostatistics, data management and real-world evidence analytics services, today announced four senior leadership appointments that further position the company for continued growth.

Key Points: 
  • Ephicacy Consulting Group, Inc., (“Ephicacy”), a leading biometrics Contract Research Organization (“CRO”) and global provider of statistical programming, biostatistics, data management and real-world evidence analytics services, today announced four senior leadership appointments that further position the company for continued growth.
  • Jim Baker as Chief Operating Officer, to oversee operations across client engagement and business development for the global company.
  • Jim brings over 35 years of experience leading bioanalytical teams at CROs and pharmaceutical companies, including at Cytel, Takeda and Amgen.
  • “I look forward to working alongside the talented team to build on this momentum, drawing on my experience helping CROs expand and scale at important moments in their lifecycle.”

Nucleus RadioPharma Announces Appointment of Chris McDonald from Kite, a Gilead Company, to Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Radiology, Pharmaceutical, Health, Oncology, Isotope, Growth, Kite, AstraZeneca, Nucleus, Novartis, Patient, Research, Cancer, Doctor of Philosophy, Radiopharmaceutical, Multimedia, Amgen, Medical imaging

Nucleus RadioPharma , the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Chris McDonald, Global Head of Technical Operations at Kite, a Gilead Company, to its Board of Directors.

Key Points: 
  • Nucleus RadioPharma , the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Chris McDonald, Global Head of Technical Operations at Kite, a Gilead Company, to its Board of Directors.
  • This addition underscores Nucleus RadioPharma's focus on operational excellence and its commitment to research and development, specifically tailored to the unique demands of the radiopharmaceutical sector.
  • View the full release here: https://www.businesswire.com/news/home/20240327530225/en/
    With the industry shifting towards isotopes that demand rapid production and distribution, McDonald's appointment is timely.
  • With Chris on board, we are poised to transform the radiopharmaceutical industry, making cancer treatments more accessible and saving the lives of patients with cancer.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Epilepsy, TPA, AIS, Patient, Tissue plasminogen activator, Stroke, G&A, Investment, Therapy, Pharmacovigilance, Nektar Therapeutics, Research, KLK1, Biostatistics, NKTR, Trial of the century, DSM-IV codes, NIHSS, Amgen, Data management, Pharmacy, Food, Cubist Pharmaceuticals, Neurology, Rankine scale, Shanghai Pharmaceuticals, DMAC, Acquisition, University, Yale University, Psychiatry, MRS, ASTN, Takeda, Patent, Bangladesh Technical Education Board, Probability, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Stromal cell, Amgen, American Chemical Society, University, Cornell University, Patient, Medicinal chemistry, Indiana University, Whitehead Institute, Doctor of Philosophy, Therapy, Drug development, Pharmacy, Division, Molecular biology, Takeda Oncology, Ironwood Pharmaceuticals, Pharmaceutical industry

Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.

Key Points: 
  • Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors.
  • Both bring deep entrepreneurial and drug development track records that will guide Nimble as it continues to pursue its internal pipeline.
  • He currently serves on the Board of Directors of Jnana Therapeutics, a role he has held since 2018.
  • "We are pleased to welcome Daniel and Brian to our Board of Directors at this important stage of Nimble’s evolution," said Jigar Patel, founder & CEO of Nimble Therapeutics.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

HemoSonics Named to Fast Company's 2024 World's Most Innovative Companies List

Retrieved on: 
Thursday, March 21, 2024
Organization, Blood transfusion, Novartis, Patient, Hospital, AI, Hope, Bristol Myers Squibb, Operating, Cartridge, Intensive care medicine, Amgen, Blood, FDA, Medicine, Pharmaceutical industry

DURHAM, N.C. , March 21, 2024 /PRNewswire/ -- HemoSonics, a medical device company focused on acute bleeding management, today announced it has been named to the prestigious list of Fast Company's Most Innovative Companies for 2024. The annual Fast Company flagship awards spotlight companies at the forefront of their respective industries and recognize organizations and products that are transforming industries through their innovations, setting new standards, and achieving remarkable milestones that are moving the world forward. HemoSonics joins previous Fast Company Most Innovative Company winners, including Abbott, Bristol Myers Squib, Novartis, Amgen, Scopio Labs and others.

Key Points: 
  • HemoSonics joins previous Fast Company Most Innovative Company winners, including Abbott, Bristol Myers Squib, Novartis, Amgen, Scopio Labs and others.
  • The World's Most Innovative Companies is Fast Company's hallmark franchise and one of the year's most anticipated awards for groundbreaking innovations.
  • Fast Company's editorial team identified the 2024 Most Innovative Companies driving progress worldwide and across industries, evaluating thousands of submissions through a competitive application process.
  • We face daunting challenges on many fronts, but the solutions we celebrate in Most Innovative Companies give me plenty of hope about the future."

Ropes & Gray Expands its Antitrust Team with Arrival of Jackie Grise

Retrieved on: 
Monday, March 18, 2024
Culture, Head, Amazon, Environment, Horizon Therapeutics, Ropes & Gray, Arena Pharmaceuticals, Sale, Acquisition, Woman, Intersect ENT, Lawyer, Therapy, Mastercard, Stent, PI, Amgen, Intersection, FTC

Jackie, a Chambers-ranked practitioner, brings more than 25 years of antitrust experience—and a strong understanding of government antitrust enforcement priorities—to Ropes & Gray's global client base.

Key Points: 
  • Jackie, a Chambers-ranked practitioner, brings more than 25 years of antitrust experience—and a strong understanding of government antitrust enforcement priorities—to Ropes & Gray's global client base.
  • She has successfully guided antitrust reviews in headline deals in which U.S. antitrust enforcers have issued "second requests."
  • Jackie expands Ropes & Gray's award-winning antitrust practice, which Chambers notes "offers top-flight representation across the full spectrum of antitrust matters," across industries where Ropes & Gray is a giant – private equity, asset management, health care, life sciences, and technology, among other key areas.
  • I am excited and proud to join the already elite, deep bench of antitrust lawyers on the team," said Jackie.